The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center Annouces it Has Been Awarded a Phase I STTR Grant from the National Eye Institute of the National Institutes of Health, Entitled "Development of a Novel Antiviral to Treat and Prevent Acyclovir Resistance in Human Ocular Herpes Keratitis"

 

Doylestown, PA. February 17, 2017- FCCDC is pleased to announce that it has been awarded a Phase I STTR from the National Eye Institute of the National Institutes of Health, entitled "Development of a Novel Antiviral to Treat and Prevent Acyclovir Resistance in Human Ocular Herpes Keratitis" (1R41EY026849-01A1).  Prof. Robert Ricciardi of the University of Pennsylvania is the Principal Investigator.